These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 19718467)

  • 1. Two cases of congenital dysfibrinogenemia associated with thrombosis - Fibrinogen Praha III and Fibrinogen Plzen.
    Kotlín R; Reicheltová Z; Malý M; Suttnar J; Sobotková A; Salaj P; Hirmerová J; Riedel T; Dyr JE
    Thromb Haemost; 2009 Sep; 102(3):479-86. PubMed ID: 19718467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two novel mutations in the fibrinogen γ nodule.
    Kotlín R; Pastva O; Stikarová J; Hlaváčková A; Suttnar J; Chrastinová L; Riedel T; Salaj P; Dyr JE
    Thromb Res; 2014 Oct; 134(4):901-8. PubMed ID: 25074738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrinogen Nový Jicín and Praha II: cases of hereditary Aalpha 16 Arg-->Cys and Aalpha 16 Arg-->His dysfibrinogenemia.
    Kotlín R; Chytilová M; Suttnar J; Riedel T; Salaj P; Blatný J; Santrůcek J; Klener P; Dyr JE
    Thromb Res; 2007; 121(1):75-84. PubMed ID: 17408725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel natural mutation AαPhe98Ile in the fibrinogen coiled-coil affects fibrinogen function.
    Riedelová-Reicheltová Z; Kotlín R; Suttnar J; Geierová V; Riedel T; Májek P; Dyr JE
    Thromb Haemost; 2014 Jan; 111(1):79-87. PubMed ID: 24108601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The fibrinogen Aalpha R16C mutation results in fibrinolytic resistance.
    Flood VH; Al-Mondhiry HA; Farrell DH
    Br J Haematol; 2006 Jul; 134(2):220-6. PubMed ID: 16846481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dusart Syndrome in a Scandinavian family characterized by arterial and venous thrombosis at young age.
    Ramanathan R; Gram J; Feddersen S; Nybo M; Larsen A; Sidelmann JJ
    Scand J Clin Lab Invest; 2013 Oct; 73(7):585-90. PubMed ID: 24000886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrinogen Šumperk II: dysfibrinogenemia in an individual with two coding mutations.
    Kotlín R; Suttnar J; Cápová I; Hrachovinová I; Urbánková M; Dyr JE
    Am J Hematol; 2012 May; 87(5):555-7. PubMed ID: 22407772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrinogen Caracas V, an abnormal fibrinogen with an Aalpha 532 Ser-->Cys substitution associated with thrombosis.
    Marchi R; Lundberg U; Grimbergen J; Koopman J; Torres A; de Bosch NB; Haverkate F; Arocha Piñango CL
    Thromb Haemost; 2000 Aug; 84(2):263-70. PubMed ID: 10959699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional characterization of fibrinogen Bicêtre II: a gamma 308 Asn-->Lys mutation located near the fibrin D:D interaction sites.
    Marchi RC; Carvajal Z; Boyer-Neumann C; Anglés-Cano E; Weisel JW
    Blood Coagul Fibrinolysis; 2006 Apr; 17(3):193-201. PubMed ID: 16575257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel fibrinogen variant--Liberec: dysfibrinogenaemia associated with gamma Tyr262Cys substitution.
    Kotlín R; Sobotková A; Suttnar J; Salaj P; Walterová L; Riedel T; Reicheltová Z; Dyr JE
    Eur J Haematol; 2008 Aug; 81(2):123-9. PubMed ID: 18485115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Partial deletion of the αC-domain in the Fibrinogen Perth variant is associated with thrombosis, increased clot strength and delayed fibrinolysis.
    Westbury SK; Duval C; Philippou H; Brown R; Lee KR; Murden SL; Phillips E; Reilly-Stitt C; Whalley D; Ariëns RA; Mumford AD
    Thromb Haemost; 2013 Dec; 110(6):1135-44. PubMed ID: 24048413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro fibrin clot formation and fibrinolysis using heterozygous plasma fibrinogen from gammaAsn319, Asp320 deletion dysfibrinogen, Otsu I.
    Terasawa F; Kani S; Hongo M; Okumura N
    Thromb Res; 2006; 118(5):651-61. PubMed ID: 16412498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel Asp344Val substitution in the fibrinogen gamma chain (fibrinogen Caen) causes dysfibrinogenemia associated with thrombosis.
    Robert-Ebadi H; Le Querrec A; de Moerloose P; Gandon-Laloum S; Borel Derlon A; Neerman-Arbez M
    Blood Coagul Fibrinolysis; 2008 Oct; 19(7):697-9. PubMed ID: 18832913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The mutation in fibrinogen Bicêtre II (gamma Asn308-->Lys) does not affect the binding of t-PA and plasminogen to fibrin.
    Grailhe P; Boyer-Neumann C; Haverkate F; Grimbergen J; Larrieu MJ; Anglés-Cano E
    Blood Coagul Fibrinolysis; 1993 Oct; 4(5):679-87. PubMed ID: 8292717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrinogen residue γAla341 is necessary for calcium binding and 'A-a' interactions.
    Park R; Ping L; Song J; Hong SY; Choi TY; Choi JR; Gorkun OV; Lord ST
    Thromb Haemost; 2012 May; 107(5):875-83. PubMed ID: 22437918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of plasmin generation and clot lysis of plasma fibrinogen purified from a heterozygous dysfibrinogenemia, BbetaGly15Cys (Hamamatsu II).
    Kamijyo Y; Hirota-Kawadobora M; Yamauchi K; Terasawa F; Honda T; Ikeya M; Okumura N
    Blood Coagul Fibrinolysis; 2009 Dec; 20(8):726-32. PubMed ID: 19809304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrinogen anomalies and disease. A clinical update.
    Galanakis DK
    Hematol Oncol Clin North Am; 1992 Oct; 6(5):1171-87. PubMed ID: 1400080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrinogen Matsumoto I: a gamma 364 Asp-->His (GAT-->CAT) substitution associated with defective fibrin polymerization.
    Okumura N; Furihata K; Terasawa F; Nakagoshi R; Ueno I; Katsuyama T
    Thromb Haemost; 1996 Jun; 75(6):887-91. PubMed ID: 8822581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrinogen Bastia (gamma 318 Asp-->Tyr) a novel abnormal fibrinogen characterized by defective fibrin polymerization.
    Lounes KC; Soria C; Valognes A; Turchini MF; Soria J; Koopman J
    Thromb Haemost; 1999 Dec; 82(6):1639-43. PubMed ID: 10613648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dysfibrinogen Kagoshima with the amino acid substitution gammaThr-314 to Ile: analyses of molecular abnormalities and thrombophilic nature of this abnormal molecule.
    Niwa K; Mimuro J; Miyata M; Sugo T; Ohmori T; Madoiwa S; Tei C; Sakata Y
    Thromb Res; 2008; 121(6):773-80. PubMed ID: 17854865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.